Recombinant vaccine against Lyme disease; comprises Borrelia burgdorferi recombinant antigen expressed by Escherichia coli which is useful in infection diagnosis

Potent Report This section provides information on worldwide patents relevant to vaccine design and production. The Patent Report gives the following information : title of patent, patentee, patent number, publication date and summary of the patent. A number of patents in this report are reproduced from 'Biotechnology Abstracts' with permission of Derwent Publications Ltd, Rochdale House, 128 Theobalds Road, London WC1X 8RD, UK. Telephone 071 242 5823. Fax 071 405 3636.

Production of recombinant vaccine against herpes virus type-I; glV antigen expression in Escherichia coli, vaccinia virus, baculovirus or adenovirus or transformed insect cell or mammal cell culture Univ. Saskatchewan World 9311 792; 24 June 1993 The following are claimed: (1) a vaccine consisting of a vehicle and at least one recombinant subunit antigen comprising a truncated cattle herpes virus type-1 (BHV-1) gIV; (2) a nucleotide sequence encoding BHV-1 gIV; (3) a D N A construct comprising an expression cassette including a DNA region encoding (2) and control sequences operably linked to the coding sequence; (4) a host stably transformed with (3); (5) production of a recombinant truncated BHV-1 gIV protein by growing the host cells so the protein is expressed and secreted, and recovering the protein from the culture medium; (6) a method for treating or preventing BHV-1 infection in cattle; and (7) a method for co-preventing or co-treating BHV-1 infection and a second bacterial or viral infection in a cattle host by administering (1) and a vaccine for the second infection. The host cell is preferably Escherichia coli, recombinant vaccinia virus, baculovirus or adenovirus, or an insect cell or a mammal cell especially transformed with a recombinant adenovirus, Rous sarcoma virus or a simian virus vector. 105-93

Live recombinant vaccine production against cattle herpes virus; D N A sequence of mutation in non-essential sequence and antibody Bayer Germany 4141 400; 17 June 1993 The use of strains of BHV-1 (cattle herpes virus) which, in comparison with wild-type virus have at least one alteration in the DNA sequence (or protein sequence) of a non-essential region of an essential protein, for the production of a recombinant vaccine, is new. Also new are: (1) BHV-1 specified DNA sequences which encode essential proteins (II) having an altered protein sequence in a non-essential region; (2) (II) having altered sequences; and (3) antibodies (Abs) raised against (II). Preferred strains have alterations in the essential glycoprotein-IV, preferably in the 310-338 amino acid region which projects outwards from the membrane covering of the virus. Specifically, BHV-1 N569 (subtype 3) is used. The modified D N A can be expressed in usual prokaryotic or eukaryotic hosts. Using these strains in vaccines allows differentiation between cattle which have been vaccinated and those which are infected with the wild-type virus. DNA sequences encoding modified (II) can be used to identify suitable strains, or for site-specific mutagenesis. (II) can be used in vaccines. 106-93

Cattle respiratory-syncytial virus anti-idiotype monoclonal antibody production from new hybridoma; application as a vaccine Int. Biotechnol World 9311 795; 24 June 1993

0264-410X/93/1411448-02 © 1993 Butterworth-HeinemannLtd 1448

Vaccine, Vol. 11, Issue 14, 1993

The following are claimed: (1) a hybridoma (I) selected to produce an anti-idiotype monoclonal antibody (mAb) immunologically reactive with an idiotypic determinant of a primary mAb, which is immunologically reactive with cattle respiratorysyncytial virus (RSV); (2) hybridoma cell line ATCC HB10901; (3) a mAb produced by (2); (4) an immunologically reactive protein presenting an antigen binding region specific to bind an idiotypic determinant of a primary mAb immunologically reactive against RSV; (5) (I), where the mAb is immunologically reactive against an idiotypic determinant either of mAb 15C7 or mAb 8G12; (6) a vaccine against RSV, comprising (I); (7) an anti-idiotypic mAb immunologically reactive with an idiotypic determinant of either mAb 15C7 or mAb 8G12; and (8) a means for labelling the anti-idiotypic mAb. The vaccine may be used for protection of cattle against RSV infection. The vaccine composition includes an anti-idiotypic mAb reactive against an idiotypic determinant of a primary antibody selected to interactably bind immune response, evoking epitopes of RSV. 107-93

Biological system for constructing and testing viral vaccines; new rabbit-pox virus RPuhr23HA+ and vector plasmid pHGN3 useful in recombinant vaccine design Univ. Florida USA 5212 057; 18 May 1993 A pure culture of rabbit-pox virus (I), designated RPuhr23HA + , is new. Also claimed is plasmid PHGN3. The culture provides a novel vector system for assay of tissue tropism and virulence potential of virus vaccines. A new predictive index concerns relative virulence and ability of a vaccine strain to grow within specific body tissues. The system may be used for the design of vaccine strains. A 'new gene' may be engineered into (I) solely for use as a cloning site. In wild-type or control strains, this gene e.g. the haemagglutinin (HA) gene, is not expressed. By using this gene as a cloning site, insertion of foreign DNA inactivates the HA gene so that any altered effects of growth or pathogenicity can only result from foreign DNA. The use of HA provides a simple colorimetric assay for potential recombinants. This system allows for identification of genetic elements responsible for specific tissue tropism and virulence of either (I) or vaccinia virus. The system may be used to detect alterations in growth of newly designed vaccine constructs, thus aiding in the development of new recombinant vaccines. 108-93

Recombinant vaccine against Lyme disease; comprises Borrelia burgdorferi recombinant antigen expressed by Eseherielda coli which is useful in infection diagnosis Univ. Minnesota World 9310 237; 27 May 1993 The following are claimed: (A) a recombinant polypeptide (at least 110 kDa) corresponding to that produced by Escherichia coli ATCC 68825 transformed with Borrelia burgdorferi DNA; (B) a pure B. burodorferi polypeptide (at least 75 kDa) recognized by monospecific antisera against the recombinant polypeptide of (A); and (C) a 7.1 kb DNA sequence which encodes a polypeptide having an amino acid sequence which corresponds to that of the recombinant 110 kDa B. burodorferi polypeptide produced by E. coli ATCC 68825. The 7.1 kb EcoRI fragment encoding the 110 kDa antigenic polypeptide was obtained from a B. burgdorferi gene bank by screening with dog antisera. The 110 kDa antigen can be used an an effective vaccine to protect against Lyme borreliosis in humans and domestic animals (including dog, cat, llama, cattle, sheep, goat and horse). The polypeptide can also be used to detect anti-

Patent Report B. burodorferi antibodies to diagnose B. burgdorferi infection or Lyme disease. Antibodies to the polypeptide can be used for passive immunization. 109-93 Recombinant vaccine to prevent pneumonia; comprises pneumococcal fimbrial protein-A expressed in Streptococcus pneumoniae; monoclonal antibody and hybridoma

U.S. Dept. Health Human Sere. World 9310 238; 27 May 1993 A vaccine providing protection against pncumococcal pneumonia is claimed comprising pneumococcai fimbrial protein-A (PfpA) or a polypeptide derived from it in an excipient. Also claimed are: (A) a DNA sequence encoding a polypeptide corresponding to PfpA (or at least five contiguous amino acids of it); (B) the polypeptide of (A) free of proteins with which it is naturally associated; (C) a recombinant DNA molecule comprising a vector and the DNA of (A); (D) a cell that contains a recombinant DNA molecule as in (C); (E) an antibody (preferably a monoclonal antibody (mAb) or binding fragment having binding affmity for PfpA; (F) a hybridoma (1E7A3D7C2) which produces the mAb of (E); and (G) aa diagnostic kit comprising the mAb. The mAb was produced using pneumococcal cells as immunogen, and then used to identify cloned Streptococcus pneumoniae DNA encoding the 37 kDa PfpA. PfpA was produced by expression in host cells and purified from S. pneumoniae cells. 110-93 Periodontal disease preventative vaccine in the form of a nasal drip administered through the nasal cavity; contains surface antigen of Porphyromonas, Actinomyces, Prevotella, Actinobacillus, Treponcma, Wolinella or Bacteroides spp.

Lion Jpn 5132 428; 28 May 1993 A new periodontal disease vaccine comprises a surface antigen from a fungus e.g. Porphyromonus gingivalis, Actinomyces

viscosus, Prevotella intermedia, Actinobacillus actinomycetemcomitans, Treponema denticola, Wolinella recta or Bacteroides forsythus. The vaccine may be administered intranasally (i.n.)

as a drip, causing no pain. I.n. introduction ensures that the antigen is not digested. Preferably, surfactant, bile acid or its salts and cholera B are added to the vaccine composition to intensify the antibody titre. Preferably the surfactant is cationic and added at 0.01-1% (preferably 0.01-0.2 wt.%). The fungi are cultured in a suitable medium, and the fungus is collected by centrifugation. An injection needle is used to isolate the fungus from the surface of the culture and the desired surface antigen is then recovered. This antigen is dissolved in saline to form a vaccine. The surface of the antigen may be treated with protease for improved vaccine use. The concentration of the antigen in the vaccine is preferably 0.005-2 rag, preferably 0.02-0.5 rag. 111-93 Fusion protein of Plasmodium circumsporozoite protein and hepatitis B virus surface antigen; expression in Saccharomyces cerevisiae for use as a recombinant vaccine for Plasmodium infection prevention

SK + Beecham World 9310 152; 27 May 1993 A fusion protein (FP) of most of the C-terminus of the Plasmodium circumsporozoite protein (CS), at least four tandem repeats of the CS protein immunodominant region and hepatitis B virus surface antigen (HBVsAg) is new. Preferably, the CS protein is amino acids 210-398 of Plasmodium falciparum 7G8 or amino acids 207-395 of P. falciparum NF54 fused in frame, optionally via a linker, to the N-terminus of HBVsAg. The following are also new: (1) a FP comprising an N-terminal Met, MetAlaPro, 189 amino acids corresponding to 210-398 or 207-395 of the CS protein of P. falciparum 7G8 and NF54, respectively, Arg, ProValThrAsn from HBV prcS2 protein, and a stretch of 226 amino acids of the HBV S protein; (2) FP RTS and RTS(star); (3) a DNA sequence encoding a FP; (4) a vector containing the DNA of (3); (5) a host, especially Saccharomyces cerevisiae, transformed with (4) and an additional HBVSAg gene; (6) a multimeric lipoprotein particle (I) containing the FP (RTS or RTS(star). optionally with HBVsAg (1:4); (7) a recombinant vaccine containing the FP; (8) a vaccination method; and (9) a process for FP or (I) production 112-93

Vaccine, Vol. 11, Issue 14, 1993 1449